Prostate Cancer
Conditions
Keywords
Metastatic castrate resistant prostate cancer mCRPC
Brief summary
Study to gather information about the optimal placement of Ra-223 in the order of different treatments in terms of the effect on patients and in terms of the use of healthcare services for the treatment of Canadian patients with prostate gland cancer which spread to other parts of the body. In order to collect this information real world data from prostate gland cancer patients from four Canadian administrative databases will be analyzed. Data collected from patients treated with their 2nd line of life-prolonging therapy for Non-Metastatic Castration Resistant Prostate Cancer (mCRPC) initiated from 01 Jan 2012 to 31 Dec 2017. For patients included in the study, all available data from the beginning for their record until death, lost to follow-up or database cut-off will be included. The index date is the date of initiation of the 2nd line life-prolonging therapy for mCRPC.
Interventions
DRUGRadium-223 dichloride (Xofigo, BAY88-8223)
Follow clinical administration
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
MALE
Healthy volunteers
No
Inclusion criteria
* Use of at least 2 lines of life-prolonging mCRPC therapy * The 2nd line of life-prolonging therapy was initiated between 01-Jan-2012 to 31-Dec-2017
Exclusion criteria
\- No formal
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | Retrospective analysis from 01-Jan-2012 to 31-Dec-2017 | The length of time from the date of initiation of 2nd line life-prolonging therapy to death due to any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Average length of hospital stays (number of days) | Retrospective analysis from 01-Jan-2012 to 31-Dec-2017 | Measured from the initiation of 2nd line life -prolonging therapy (index date) until death |
| Time to first Emergency Room (ER) visit | Retrospective analysis from 01-Jan-2012 to 31-Dec-2017 | Measured from the start of 2nd line life-prolonging therapy (index date) until the first ER visit. |
| Event-free survival (EFS) | Retrospective analysis from 01-Jan-2012 to 31-Dec-2017 | The length of time from the start of 2nd line life-prolonging therapy to the earliest occurrence of one of the following: * A change in life-prolonging treatment * Death from any cause |
| Number of overnight hospital stays | Retrospective analysis from 01-Jan-2012 to 31-Dec-2017 | Measured from the initiation of 2nd line life-prolonging therapy (index date) until death |
| Total incidence of EBRT | Retrospective analysis from 01-Jan-2012 to 31-Dec-2017 | Total number of EBRT treatments received over the course of the patient's journey starting from the initiation of 2nd line life-prolonging therapy (index date) until death. |
| Time to first hospitalization | Retrospective analysis from 01-Jan-2012 to 31-Dec-2017 | Measured from the start of the 2nd line life-prolonging therapy (index date) until the first overnight hospital stay. |
| Number of visits to the ER | Retrospective analysis from 01-Jan-2012 to 31-Dec-2017 | Measured from the initiation of 2nd line life-prolonging therapy (index date) until death |
| Time to External Beam Radiation Therapy (EBRT) | Retrospective analysis from 01-Jan-2012 to 31-Dec-2017 | From the start of the 1st life-prolonging therapy (index date) until the first use of EBRT |
Countries
Canada
Outcome results
None listed